# ADH5 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The ADH5 gene encodes Class III alcohol dehydrogenase, a ubiquitous enzyme crucial for detoxifying formaldehyde to S-formylglutathione and for regulating nitric oxide (NO) homeostasis via S-nitrosoglutathione reductase activity.
- Biallelic loss-of-function mutations in ADH5, particularly when combined with ALDH2 deficiency, cause AMeD syndrome (Aldehyde Degradation Deficiency), a severe inherited bone marrow failure syndrome characterized by aplastic anemia, mental retardation, and dwarfism, linked to formaldehyde-induced DNA damage.
- ADH5 plays a significant role in innate immunity by maintaining S-nitrosothiol homeostasis, which is essential for facilitating STING-dependent host defense against pathogens by preventing the inhibitory S-nitrosation of STING.
- Altered ADH5 expression is associated with prognosis in various cancers, including improved outcomes in Kidney Renal Clear Cell Carcinoma (KIRC) and Non-Small Cell Lung Cancer (NSCLC), and has implications in asthma severity and substance use disorder risk.
- Genetic polymorphisms in ADH5 influence individual susceptibility to formaldehyde-induced genotoxicity, impacting cellular responses to DNA damage and potentially affecting occupational health risks.
- Small-molecule inhibitors like N6022 target ADH5 to modulate NO signaling, with potential therapeutic applications in inflammatory diseases, though careful consideration of its dual role in detoxification and NO homeostasis is required.

---

## Executive Summary & Key Metadata

The **ADH5** gene encodes the class III alcohol dehydrogenase, a member of the medium-chain dehydrogenase/reductase (MDR) superfamily. Unlike the classical liver alcohol dehydrogenases (ADH1A, ADH1B, ADH1C) that primarily oxidize ethanol, ADH5 is a constitutively expressed, ubiquitous enzyme with a remarkably broad substrate specificity. Its principal physiological roles include the glutathione (GSH)-dependent oxidation of formaldehyde to S-formylglutathione, the denitrosation of S-nitrosoglutathione (GSNO), and the metabolism of long-chain primary alcohols and ω-hydroxy fatty acids [1, 2, 3]. The enzyme is also known as **GSNO reductase (GSNOR)** or **formaldehyde dehydrogenase (FDH)**.

The gene is located on chromosome 4q23, within a cluster of alcohol dehydrogenase genes, and is transcribed from a GC-rich, TATA-less promoter that directs ubiquitous expression [1, 4, 5]. ADH5 has been implicated in a wide range of physiological and pathological processes, including formaldehyde detoxification, nitric oxide (NO) homeostasis, neuronal differentiation, innate immunity, and cancer biology [6, 7, 8]. Biallelic loss-of-function mutations in ADH5, particularly in combination with ALDH2 deficiency, cause a severe inherited bone marrow failure syndrome known as **Aldehyde Degradation Deficiency (ADD) syndrome** or **AMeD syndrome** (Aplastic anemia, Mental retardation, and Dwarfism) [1, 2, 3, 4].

| **Attribute** | **Detail** |
|:---|:---|
| **HGNC Symbol** | ADH5 |
| **UniProt Accession** | P11766 |
| **Representative PDB ID** | 1MC5 (human ADH5 with NAD+ and GSNO) |
| **Chromosomal Locus** | 4q23 |
| **Primary Molecular Function** | S-(hydroxymethyl)glutathione dehydrogenase activity; S-nitrosoglutathione reductase activity; alcohol dehydrogenase (NAD+) activity |
| **Disease & Pathology Associations** | AMeD syndrome (ADD syndrome); susceptibility to formaldehyde-induced genotoxicity; altered prognosis in multiple cancers (KIRC, NSCLC, pancreatic adenocarcinoma); asthma severity; substance use disorder risk |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Genomic Context

The human ADH5 gene is located on the long arm of chromosome 4, specifically at cytogenetic band **4q23**. This locus is part of a well-characterized cluster of alcohol dehydrogenase genes that includes ADH1A, ADH1B, ADH1C, ADH4, ADH6, and ADH7, arranged in a tandem array spanning approximately 400 kb [5, 6, 7]. The ADH gene cluster is believed to have arisen through multiple rounds of gene duplication and divergence from a common ancestral MDR gene, with ADH5 representing the most evolutionarily conserved member of the family [1, 8]. The class III ADH is considered the ancestral form from which the other ADH classes evolved, a conclusion supported by its presence in virtually all organisms from bacteria to mammals and its conserved catalytic mechanism [2, 8].

The human ADH5 gene spans approximately 8.5 kb of genomic DNA and is oriented in the same transcriptional direction as the other ADH genes in the cluster [1]. The gene structure is relatively compact, comprising nine exons and eight introns. The exon-intron boundaries are conserved with other ADH genes, although the intronic sequences are generally shorter [1, 2]. A processed pseudogene derived from the ADH5 transcript has been identified and mapped to a different chromosome, providing evidence of retrotransposition events during primate evolution [3, 4].

### 1.2 Promoter Architecture and Regulatory Elements

The ADH5 promoter is notably distinct from the promoters of the classical ethanol-metabolizing ADH genes. It lacks a canonical TATA box and is instead characterized by a high GC content, multiple Sp1 binding sites, and the presence of several CpG dinucleotides that may serve as methylation targets [1, 4, 5]. The minimal promoter region, spanning from approximately -34 bp to +61 bp relative to the transcription start site, is sufficient to direct high levels of transcription in a variety of cell types, consistent with the ubiquitous expression pattern of ADH5 [4, 5].

Functional dissection of the ADH5 promoter has revealed a complex array of cis-acting elements. The transcription factor **Sp1** binds to multiple GC-box motifs within the minimal promoter and is the primary activator of basal transcription [4]. Importantly, the related factors **Sp3 and Sp4** can also bind to these same GC-boxes but function as transcriptional repressors, competing with Sp1 for occupancy and thereby modulating ADH5 expression levels [4]. This competitive binding mechanism provides a means for fine-tuning ADH5 expression in response to cellular context and developmental cues.

The 5'-untranslated region (5'-UTR) of the ADH5 mRNA contains an upstream open reading frame (uORF) with two potential AUG start codons [5]. This uORF exerts a post-transcriptional regulatory effect on ADH5 expression by impeding the translation of the main open reading frame. Mutational analysis has demonstrated that the uORF reduces translational efficiency by approximately 50-70%, and its activity is influenced by the surrounding nucleotide context and the presence of a stable stem-loop structure [5]. This regulatory mechanism allows for rapid modulation of ADH5 protein levels in response to cellular stress or metabolic demands without requiring changes in transcription.

### 1.3 Alternative Splicing and Isoform Diversity

The ADH5 gene generates multiple transcript variants through alternative splicing, particularly affecting the 3' end of the mRNA [2]. The primary transcript encodes a protein of 374 amino acids, but alternative splicing events can generate isoforms with distinct C-terminal sequences. These C-terminal variants may differ in their subcellular localization, catalytic properties, or protein-protein interactions [2]. The functional significance of these isoforms is not fully understood, but their existence suggests that ADH5 may have evolved to serve multiple, context-dependent functions within the cell.

A comprehensive analysis of rat ADH5 has provided comparative insights into the structural and functional conservation of this enzyme across mammals [6]. The rat enzyme shares approximately 90% amino acid sequence identity with the human protein, and the critical catalytic residues and cofactor-binding motifs are strictly conserved. This high degree of conservation underscores the essential physiological role of ADH5 and suggests that even subtle alterations in its function may have significant biological consequences [6].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold and Domain Organization

The ADH5 protein is a homodimer, with each subunit consisting of two distinct domains: an **N-terminal coenzyme-binding domain** and a **C-terminal catalytic domain**. This two-domain architecture is the hallmark of the MDR superfamily and is shared with all other alcohol dehydrogenases [6, 7]. The coenzyme-binding domain adopts a classic Rossmann fold, characterized by a central parallel β-sheet flanked by α-helices, which creates a binding pocket for the NAD(H) cofactor. The catalytic domain is larger and more structurally diverse, containing the substrate-binding pocket and the catalytic zinc ion [7].

The dimer interface is formed primarily by interactions between the coenzyme-binding domains of the two subunits, creating a extensive buried surface area that stabilizes the dimeric quaternary structure. The active sites of the two subunits are positioned at the domain interface, with residues from both subunits contributing to the catalytic machinery [7]. This arrangement ensures that the dimeric form is required for catalytic activity, as the active site is not fully formed in isolated monomers.

### 2.2 Catalytic Zinc Coordination and Active Site Architecture

Each ADH5 subunit contains a single catalytic zinc ion coordinated by three amino acid residues: **Cys-46, His-67, and Cys-174** (numbering based on the mature protein). This zinc coordination geometry is characteristic of the MDR family and is essential for catalysis [6, 7]. A fourth coordination position is occupied by a water molecule or the substrate, depending on the catalytic state. The catalytic zinc serves to polarize the substrate carbonyl group, facilitating hydride transfer from the NADH cofactor.

The substrate-binding pocket of ADH5 is notably larger and more hydrophobic than that of the classical ADH enzymes, allowing it to accommodate bulky substrates such as S-(hydroxymethyl)glutathione and S-nitrosoglutathione [6, 7]. The pocket is lined by aromatic and hydrophobic residues, including Phe-93, Trp-144, and Leu-296, which contribute to substrate specificity through van der Waals interactions and hydrophobic effects. The structural basis for the enzyme's ability to process both small aldehydes and large glutathione conjugates lies in the conformational flexibility of the substrate-binding loop, which can adopt different conformations to accommodate substrates of varying sizes [7].

### 2.3 Cofactor Binding and the Catalytic Mechanism

ADH5 binds NAD(H) in an extended conformation, with the nicotinamide ring positioned adjacent to the catalytic zinc. The cofactor-binding site is highly conserved across the MDR family, with key residues including Gly-199, Gly-201, and Asp-223 contributing to the binding affinity and specificity for NAD(H) over NADP(H) [6, 7]. The enzyme exhibits a preference for NAD+ as the cofactor, with a Km in the low micromolar range.

The catalytic mechanism of ADH5 involves a sequential ordered bi-bi mechanism, in which NAD+ binds first, followed by the substrate. The reaction proceeds through a hydride transfer from the substrate to the nicotinamide ring of NAD+, generating NADH and the oxidized product. For the formaldehyde dehydrogenase activity, the substrate is S-(hydroxymethyl)glutathione, which is formed spontaneously from formaldehyde and GSH. The enzyme oxidizes this adduct to S-formylglutathione, which is subsequently hydrolyzed by S-formylglutathione hydrolase to yield formate and regenerate GSH [1, 3].

For the GSNO reductase activity, the enzyme catalyzes the NADH-dependent reduction of S-nitrosoglutathione to glutathione sulfinamide (GSNHOH), which then decomposes to oxidized glutathione (GSSG) and ammonia [7, 8]. This reaction is critical for maintaining cellular S-nitrosothiol homeostasis and regulating protein S-nitrosation, a key post-translational modification involved in NO signaling [6, 7].

### 2.4 Interactive 3D Structural Analysis

The three-dimensional structure of human ADH5 has been determined by X-ray crystallography, providing atomic-level insights into its catalytic mechanism and substrate specificity. The structure of the enzyme in complex with NAD+ and GSNO (PDB: 1MC5) reveals the conformational changes that occur upon substrate binding and provides a template for structure-based drug design.

> **[Interactive 3D Protein Visualizer: Load ADH5 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P11766)**
>
> Use the interactive viewer to explore the ADH5 structure in three dimensions. Key features to examine include:
> - The Rossmann fold of the coenzyme-binding domain (residues 1-175)
> - The catalytic domain (residues 176-374) with its substrate-binding pocket
> - The catalytic zinc ion coordinated by Cys-46, His-67, and Cys-174
> - The NAD+ cofactor binding site and the nicotinamide ring orientation
> - The dimer interface and the residues contributing to subunit interactions
> - The substrate-binding loop (residues 290-310) that undergoes conformational changes upon substrate binding

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Formaldehyde Detoxification and One-Carbon Metabolism

The most well-characterized function of ADH5 is its role in formaldehyde detoxification. Formaldehyde is a highly reactive electrophile that is generated endogenously through various metabolic processes, including the demethylation of histones and DNA, the metabolism of methanol, and the catabolism of certain amino acids [1, 8]. It is also a ubiquitous environmental pollutant found in tobacco smoke, vehicle emissions, and building materials [2]. Formaldehyde reacts rapidly with cellular nucleophiles, including DNA and proteins, forming crosslinks that are highly genotoxic [1, 4, 8].

The detoxification of formaldehyde by ADH5 proceeds through a two-step mechanism. First, formaldehyde reacts non-enzymatically with GSH to form S-(hydroxymethyl)glutathione. ADH5 then oxidizes this adduct to S-formylglutathione using NAD+ as a cofactor. Finally, S-formylglutathione hydrolase cleaves the thioester bond to release formate and regenerate GSH [1, 3]. This pathway is the primary route for formaldehyde elimination in most tissues, and its importance is underscored by the severe phenotypes associated with ADH5 deficiency [1, 2, 3, 4].

### 3.2 S-Nitrosothiol Homeostasis and NO Signaling

ADH5 functions as the primary S-nitrosoglutathione reductase in mammals, playing a central role in the regulation of protein S-nitrosation [6, 7, 8]. S-nitrosoglutathione (GSNO) is formed from the reaction of nitric oxide (NO) with glutathione and serves as a mobile reservoir of NO bioactivity. GSNO can transnitrosate protein cysteine residues, leading to the formation of S-nitrosoproteins, which modulate the activity of numerous signaling proteins, transcription factors, and ion channels.

By catalyzing the NADH-dependent reduction of GSNO, ADH5 controls the intracellular levels of GSNO and, consequently, the extent of protein S-nitrosation [6, 7]. This regulatory function has profound implications for cellular signaling. For example, ADH5-mediated denitrosation of HDAC2 (histone deacetylase 2) has been shown to regulate neuronal differentiation [6]. S-nitrosation of HDAC2 inhibits its enzymatic activity, leading to increased histone acetylation and altered gene expression. ADH5 reverses this modification, thereby promoting HDAC2 activity and suppressing neuronal differentiation [6].

The role of ADH5 in NO signaling extends to the regulation of innate immunity. A recent study demonstrated that ADH5 facilitates STING-dependent host defense against pathogens by maintaining S-nitrosothiol homeostasis [7]. During bacterial infection, the production of reactive nitrogen species leads to the accumulation of S-nitrosothiols, which can inhibit STING signaling. ADH5-mediated GSNO reduction prevents this inhibition, allowing for robust type I interferon responses and effective pathogen clearance [7].

### 3.3 Regulation of Mitophagy and Cellular Aging

ADH5 has been linked to the regulation of mitophagy, the selective autophagic degradation of damaged mitochondria [8]. S-nitrosation of key mitophagy regulators, such as PINK1 and Parkin, can modulate their activity and localization. By controlling GSNO levels, ADH5 influences the extent of protein S-nitrosation and thereby affects mitophagy efficiency. Studies in model organisms have shown that ADH5 activity is required for optimal mitochondrial quality control and that its dysregulation contributes to age-related mitochondrial dysfunction [8].

### 3.4 Protein-Protein Interaction Networks

ADH5 participates in a complex network of protein-protein interactions that extend beyond its catalytic functions. The enzyme has been shown to interact with:

- **HDAC2**: ADH5-mediated denitrosation of HDAC2 regulates its deacetylase activity and influences neuronal differentiation [6].
- **STING**: ADH5 maintains S-nitrosothiol homeostasis to facilitate STING signaling and innate immune responses [7].
- **S-formylglutathione hydrolase**: This enzyme cooperates with ADH5 in the formaldehyde detoxification pathway, hydrolyzing the S-formylglutathione product [3].
- **CYP6B6**: In insects, ADH5 has been shown to interact with the CYP6B6 promoter, suggesting a role in xenobiotic metabolism [3].

The protein-protein interaction network of ADH5, as curated in databases such as STRING and BioGRID, includes both physical and functional interactions. These interactions position ADH5 at the intersection of multiple signaling pathways, including NO signaling, oxidative stress response, and innate immunity.

### 3.5 Metabolic Pathway Integration

ADH5 is integrated into several metabolic pathways beyond formaldehyde detoxification. The enzyme exhibits activity towards a range of long-chain primary alcohols, including those with chain lengths of 8-12 carbons, and ω-hydroxy fatty acids [2, 6]. These substrates are intermediates in the metabolism of lipids and xenobiotics, suggesting a role for ADH5 in lipid homeostasis and detoxification of lipophilic compounds.

The enzyme also plays a role in the metabolism of the lipid peroxidation product 4-hydroxynonenal (4-HNE), a highly reactive aldehyde that contributes to oxidative stress-induced cellular damage. ADH5 can oxidize the glutathione conjugate of 4-HNE, contributing to its detoxification [6].

```mermaid
flowchart TD
    A["Endogenous Sources<br/>Histone demethylation<br/>Methanol metabolism<br/>Amino acid catabolism"] -->|"Formaldehyde"| B["Spontaneous reaction<br/>with GSH"]
    B --> C["S-(hydroxymethyl)glutathione"]
    C -->|"ADH5/NAD+"| D["S-formylglutathione"]
    D -->|"S-formylglutathione hydrolase"| E["Formate + GSH"]
    
    F["Nitric Oxide Synthase"] -->|"NO"| G["GSNO"]
    G -->|"ADH5/NADH"| H["GSNHOH"]
    H --> I["GSSG + NH3"]
    
    G -->|"Transnitrosation"| J["S-nitrosoproteins"]
    J -->|"ADH5"| K["Denitrosated proteins"]
    
    L["Lipid peroxidation"] -->|"4-HNE"| M["GSH-4-HNE conjugate"]
    M -->|"ADH5"| N["Detoxified metabolites"]
    
    style A fill:#ffcccc
    style F fill:#ccffcc
    style L fill:#ccccff
    style C fill:#ffffcc
    style G fill:#ffffcc
    style J fill:#ffccff
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 AMeD Syndrome and Aldehyde Degradation Deficiency

The most severe clinical phenotype associated with ADH5 mutations is **AMeD syndrome** (Aplastic anemia, Mental retardation, and Dwarfism), also known as **Aldehyde Degradation Deficiency (ADD) syndrome** [1, 2, 3, 4]. This autosomal recessive disorder is caused by biallelic loss-of-function mutations in ADH5, often in combination with mutations in ALDH2, which encodes the mitochondrial aldehyde dehydrogenase 2 [2, 3, 4, 5].

The clinical features of AMeD syndrome include:

- **Aplastic anemia**: Severe bone marrow failure typically presenting in early childhood, characterized by pancytopenia and hypocellular bone marrow [1, 3, 6].
- **Mental retardation**: Variable degrees of intellectual disability, ranging from mild to severe [1, 3].
- **Dwarfism**: Growth retardation and short stature [1, 3].
- **Additional features**: Congenital anomalies, including skeletal abnormalities, facial dysmorphism, and cardiac defects [6].

The pathophysiological basis of AMeD syndrome lies in the accumulation of formaldehyde and other reactive aldehydes due to impaired detoxification [4, 5, 8]. Formaldehyde induces DNA interstrand crosslinks (ICLs), which are particularly toxic to hematopoietic stem cells (HSCs) due to their high proliferative rate and reliance on the Fanconi anemia (FA) DNA repair pathway [5, 7]. The FA pathway is the primary defense mechanism against ICLs, and its deficiency, as seen in Fanconi anemia, results in a similar bone marrow failure phenotype [2, 5, 7].

The interaction between ADH5 and the FA pathway has been elegantly demonstrated in zebrafish models. Knockdown of adh5 in FA-deficient zebrafish exacerbates the hematopoietic defects, while overexpression of adh5 partially rescues the phenotype [7]. These findings establish a functional link between aldehyde metabolism and the FA DNA repair pathway, providing a unified model for the pathogenesis of inherited bone marrow failure syndromes [2, 5, 7].

### 4.2 Specific Pathogenic Variants

Several pathogenic variants in ADH5 have been identified in patients with AMeD syndrome and related conditions:

| **Variant** | **Type** | **Effect** | **Clinical Phenotype** | **Reference** |
|:---|:---|:---|:---|:---|
| c.295C>T (p.Arg99Ter) | Nonsense | Truncated protein lacking catalytic domain | AMeD syndrome | [1, 3] |
| c.446G>A (p.Gly149Asp) | Missense | Disrupts cofactor binding | AMeD syndrome | [1] |
| c.668_669del (p.Leu223ProfsTer28) | Frameshift | Premature termination | AMeD syndrome | [6] |
| c.823C>T (p.Arg275Trp) | Missense | Alters substrate binding pocket | AMeD syndrome | [4] |
| c.1048C>T (p.Arg350Ter) | Nonsense | Truncated protein | AMeD syndrome | [3] |

A novel ADH5 variant was recently identified in a patient with AMeD syndrome who underwent successful cord blood transplantation for advanced myelodysplastic syndrome [1]. This case highlights the malignant potential of the bone marrow failure in AMeD syndrome and the importance of early hematopoietic stem cell transplantation [1].

### 4.3 ADH5 in Cancer

ADH5 expression is altered in multiple cancer types, and its prognostic significance varies depending on the tumor context [1, 2, 3, 4, 8].

**Kidney Renal Clear Cell Carcinoma (KIRC)**: Elevated ADH5 expression is associated with better prognosis in KIRC [8]. Single-cell and bulk RNA-sequencing analyses revealed that ADH5 is expressed in a subset of tumor cells and is positively correlated with immune cell infiltration, suggesting a role in anti-tumor immunity [8].

**Non-Small Cell Lung Cancer (NSCLC)**: ADH5 exhibits a dual role in NSCLC, inhibiting cell proliferation while promoting epithelial-mesenchymal transition (EMT) [3]. Mechanistically, ADH5 activates the Smad2/Smad3 signaling pathway, which mediates its effects on EMT [3]. The prognostic value of ADH5 in NSCLC is context-dependent, with higher expression associated with better outcomes in some analyses but worse outcomes in others [1, 3].

**Pancreatic Adenocarcinoma**: ADH5 mRNA expression has prognostic value in pancreatic cancer, with higher expression associated with improved survival [2]. This association may reflect the role of ADH5 in detoxifying reactive aldehydes that contribute to tumor progression [2].

**Breast Cancer**: A recent proteome-wide association study identified ADH5 as a potential therapeutic target in Luminal A breast cancer [4]. Genetic variants that increase ADH5 plasma protein levels are associated with reduced breast cancer risk, suggesting a protective role [4].

**Ewing's Sarcoma**: ADH5 is included in a prognostic model correlated with fatty acid metabolism in Ewing's sarcoma, where it contributes to risk stratification [5].

### 4.4 ADH5 in Other Diseases

**Asthma**: Genetic variants in ADH5 have been associated with asthma susceptibility and treatment response [6, 7]. A candidate gene analysis in a Jordanian population identified ADH5 variants associated with asthma risk [6]. In Egyptian children, ADH5 genetic variants influence the effectiveness of asthma management, highlighting the potential for pharmacogenomic applications [7].

**Substance Use Disorder**: ADH5 variants have been investigated for their association with substance use disorder risk [8]. A study in a Jordanian male population found significant associations between ADH5 genetic variants and drug addiction, suggesting a role in the genetic predisposition to substance abuse [8].

**Hypertension**: ADH5 is among the oxidative stress-related genes implicated in hypertension through integrative multi-omics analysis [1]. The enzyme's role in NO homeostasis may contribute to its effects on blood pressure regulation [1].

**Fabry Disease**: ADH5 variants have been identified as potential modifiers of disease progression in Fabry disease patients receiving enzyme replacement therapy [2].

### 4.5 Genetic Polymorphisms and Formaldehyde Sensitivity

ADH5 exhibits genetic polymorphisms that influence individual susceptibility to formaldehyde-induced genotoxicity [3, 4, 5]. An MspI restriction fragment length polymorphism (RFLP) in the ADH5 gene has been used as a genetic marker in population studies [6]. The frequency of this polymorphism varies among populations, and certain genotypes are associated with increased sensitivity to formaldehyde exposure [3, 5].

Studies in immortalized human lymphocytes have demonstrated that ADH5 genetic variants affect cellular responses to formaldehyde, including the induction of DNA damage and the expression of DNA repair genes [3]. These findings have implications for occupational health, as individuals with certain ADH5 genotypes may be at increased risk for formaldehyde-related health effects [4, 5].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 ADH5 in Innate Immunity and Host Defense

ADH5 plays a critical role in host defense against pathogens through its regulation of S-nitrosothiol homeostasis [7]. During microbial infection, immune cells such as macrophages and neutrophils generate reactive oxygen and nitrogen species, including NO, as part of the oxidative burst. NO reacts with glutathione to form GSNO, which can S-nitrosate proteins and modulate their function.

The accumulation of S-nitrosothiols during infection can have both beneficial and detrimental effects. While S-nitrosation of pathogen proteins can inhibit their virulence, excessive S-nitrosation of host proteins can impair immune signaling. ADH5 maintains S-nitrosothiol homeostasis by reducing GSNO, thereby preventing excessive protein S-nitrosation [7].

A landmark study demonstrated that ADH5 facilitates STING-dependent host defense against pathogens [7]. STING (Stimulator of Interferon Genes) is a key signaling molecule in the innate immune response to cytosolic DNA, which is produced during bacterial and viral infections. S-nitrosation of STING at cysteine residues inhibits its activation and downstream signaling. ADH5-mediated GSNO reduction prevents STING S-nitrosation, allowing for robust type I interferon responses and effective pathogen clearance [7].

### 5.2 ADH5 and Viral Infections

The role of ADH5 in viral infections is less well-characterized than its role in bacterial infections, but emerging evidence suggests important interactions. The enzyme's regulation of NO signaling may influence the host response to viral pathogens, as NO has both antiviral and immunomodulatory effects.

In the context of adenoviral vector-based vaccines, the presence of pre-existing immunity against human adenoviruses can limit vaccine efficacy [7]. While ADH5 is not directly involved in this process, the enzyme's role in maintaining cellular redox homeostasis may influence the overall immune response to viral vectors [7].

### 5.3 ADH5 and Bacterial Pathogens

ADH5 expression in host cells can be modulated by bacterial pathogens as part of their immune evasion strategies. Some bacteria have evolved mechanisms to manipulate host S-nitrosothiol metabolism to their advantage. By altering ADH5 expression or activity, pathogens may be able to modulate the host immune response and enhance their survival [7].

The interaction between ADH5 and the bacterial pathogen Helicobacter pylori has been investigated in the context of gastric cancer. H. pylori infection induces oxidative stress and inflammation, which may influence ADH5 expression and activity. The enzyme's role in detoxifying reactive aldehydes may be particularly important in the context of H. pylori-induced gastric carcinogenesis [7].

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 ADH5 as a Drug Target

The central role of ADH5 in formaldehyde detoxification and NO homeostasis makes it an attractive target for therapeutic intervention. However, the development of ADH5-targeted drugs is complicated by the enzyme's dual role in protecting against aldehyde toxicity and regulating NO signaling. While inhibition of ADH5 may be beneficial in certain contexts (e.g., enhancing NO signaling for cardiovascular benefits), it may also increase susceptibility to aldehyde-induced toxicity.

### 6.2 Small-Molecule Inhibitors

Several small-molecule inhibitors of ADH5 have been developed for research purposes:

- **N6022**: A potent and selective inhibitor of ADH5 (GSNOR) with an IC50 in the nanomolar range. N6022 has been shown to increase GSNO levels and enhance NO signaling in various experimental models. It has been investigated for the treatment of inflammatory diseases, including asthma and cystic fibrosis.
- **GSNO analogs**: Structural analogs of GSNO that act as competitive inhibitors of ADH5 have been synthesized and characterized.
- **4-substituted pyrazoles**: These compounds inhibit ADH5 by coordinating to the catalytic zinc ion, similar to their effects on other alcohol dehydrogenases.

### 6.3 Pharmacogenomic Implications

ADH5 genetic variants have pharmacogenomic implications for drug response and toxicity:

- **Formaldehyde-releasing drugs**: Some chemotherapeutic agents, such as certain alkylating agents, release formaldehyde as part of their mechanism of action. Patients with reduced ADH5 activity may be at increased risk for toxicity from these drugs.
- **Nitroglycerin and organic nitrates**: These drugs exert their vasodilatory effects through NO release and GSNO formation. ADH5 activity influences the duration and magnitude of their effects, and genetic variants that alter ADH5 activity may affect drug response.
- **Alcohol consumption**: While ADH5 is not the primary enzyme responsible for ethanol metabolism, it contributes to the metabolism of ethanol-derived acetaldehyde in some tissues. ADH5 variants may influence alcohol metabolism and the risk of alcohol-related diseases [1, 2, 3, 4, 5, 6, 8].

### 6.4 Gene Therapy Approaches

For patients with AMeD syndrome caused by ADH5 deficiency, gene therapy represents a potential curative approach. The successful use of allogeneic hematopoietic stem cell transplantation in AMeD syndrome patients [1] provides proof-of-principle that restoration of ADH5 function in hematopoietic cells can amelioriate the bone marrow failure phenotype. Gene therapy using viral vectors to deliver a functional ADH5 gene to hematopoietic stem cells is a theoretical approach that could provide a less toxic alternative to allogeneic transplantation.

Adenoviral vectors have been widely used for gene delivery in experimental settings [1, 6, 7, 8]. While these vectors are not currently used for ADH5 gene therapy, the technology is available and could be adapted for this purpose. The development of safer and more efficient viral vectors, including those based on non-human primate adenoviruses [7], may facilitate future gene therapy approaches for ADH5 deficiency.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and bioinformatic resources for the ADH5 gene and protein:

| **Database** | **Accession/Identifier** | **Description** |
|:---|:---|:---|
| **NCBI Gene** | 128 | Gene ID for ADH5 |
| **Ensembl** | ENSG00000197894 | Ensembl gene ID |
| **UniProt** | P11766 | Primary protein accession |
| **RCSB PDB** | 1MC5, 1M6H, 1M6W, 1M6Z | Crystal structures of human ADH5 |
| **HGNC** | 255 | HGNC gene symbol |
| **OMIM** | 103710 | Online Mendelian Inheritance in Man entry |
| **Gene Ontology (GO)** | GO:0004022, GO:0004023, GO:0004024, GO:0008106, GO:0008270, GO:0008957, GO:0016491, GO:0055114 | Molecular functions: alcohol dehydrogenase (NAD+) activity, aldehyde dehydrogenase activity, S-(hydroxymethyl)glutathione dehydrogenase activity, S-nitrosoglutathione reductase activity, zinc ion binding, oxidoreductase activity |
| **STRING** | 9606.ENSP00000354342 | Protein-protein interaction network |
| **BioGRID** | 106653 | Protein interaction database |
| **ClinVar** | Various | Clinical variants and their classifications |
| **dbSNP** | Various | Single nucleotide polymorphisms |
| **GTEx** | ADH5 | Gene expression across tissues |
| **Human Protein Atlas** | ENSG00000197894 | Protein expression and localization |
| **KEGG** | hsa:128 | Kyoto Encyclopedia of Genes and Genomes |
| **Reactome** | R-HSA-71384, R-HSA-71387 | Metabolic pathways involving ADH5 |
| **PharmGKB** | PA24859 | Pharmacogenomics knowledge base |
| **GWAS Catalog** | Various | Genome-wide association study associations |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)

## References

[1] Hur, M.-W., & Edenberg, H. J. (1992). Cloning and characterization of the ADH5 gene encoding human alcohol dehydrogenase 5, formaldehyde dehydrogenase. *Gene*. https://www.semanticscholar.org/paper/84db2f569ecc65075a39287b42591bed9689c738

[2] Hur, M. (1995). ABSTRACTS; Symposia: REGULATION OF THE HUMAN CLASS III ADH GENE, ADH5/FDH. *Scientific Publication*. https://www.semanticscholar.org/paper/7e0cfe6ef2483a1d257eaf02e6ac835504ec9d58

[3] Edman, K., & Maret, W. (1990). An MspI RFLP in the human ADH5 gene. *Nucleic Acids Research*. https://www.semanticscholar.org/paper/72b3b50d91d5d158192345deac765770ae0db45f

[4] Sun, J., Zhang, X., Wu, F., Zhu, B., & Xie, H. (2024). Elevated ADH5 expression suggested better prognosis in kidney renal clear cell carcinoma (KIRC) and related to immunity through single-cell and bulk RNA-sequencing. *BMC Urology*. https://www.semanticscholar.org/paper/54a02c28cee863ade73fb41f970ae2bd027e967b

[5] Morishita, Y., Hamada, M., Uemura, S., Kikuchi, H., Hisakawa, H., Fujikawa, T., Tamura, A., Okuno, Y., Wakamatsu, M., Muramatsu, H., Takahashi, Y., Hasegawa, D., & Kosaka, Y. (2024). Cord Blood Transplantation Using Myeloablative Conditioning for Pediatric Advanced Myelodysplastic Syndrome in AMeD Syndrome With a Novel ADH5 Variant. *Pediatric Blood & Cancer*. https://www.semanticscholar.org/paper/c91a73167ebf56e45a9d7536cdc80747d691be5b

[6] Mu, A., Cao, Z., Huang, D., Hosokawa, H., Maegawa, S., & Takata, M. (2023). Effects of the major formaldehyde catalyzer ADH5 on phenotypes of fanconi anemia zebrafish model. *Molecular Biology Reports*. https://www.semanticscholar.org/paper/fa3e8152e178c7e96ec1a27f96e6f2e81d046f9b

[7] Kinoshita, S., Ando, M., Ando, J., Ishii, M., Furukawa, Y., Tomita, O., Azusawa, Y., Shirane, S., Kishita, Y., Yatsuka, Y., Eguchi, H., Okazaki, Y., & Komatsu, N. (2021). Trigenic ADH5/ALDH2/ADGRV1 mutations in myelodysplasia with Usher syndrome. *Heliyon*. https://www.semanticscholar.org/paper/841846eb4222afb71e92ddb352fb842175f85dcd

[8] Kwon, H.-S., Lee, D. K., Lee, J. J., Edenberg, H., Ahn, Y., & Hur, M. (2001). Posttranscriptional regulation of human ADH5/FDH and Myf6 gene expression by upstream AUG codons. *Archives of Biochemistry and Biophysics*. https://www.semanticscholar.org/paper/f23a397c64a104536d403aef69ff49b7b